rogen therapy include
certain cardiovascular disorders, certain malignant neoplasms, dementia,
gallbladder disease, hypercalcemia and visual abnormalities. The most
frequently reported adverse events in Divigel(R) clinical trials were
nasopharyngitis, upper respiratory tract infection, vaginal mycosis, breast
tenderness and metrorrhagia.
Estrogens with or without progestins should be prescribed at the lowest
effective doses and for the shortest duration consistent with treatment
goals and risks for the individual woman.
This safety information is not all-inclusive. Please see full
prescribing information, including black box and other warnings. For more
information, call 800-654-2299 or visit http://www.divigelus.com.
Orion Corporation (OMX: ORNAV, ORNBV) has a licensing agreement with
Upsher-Smith Laboratories for the development of Divigel(R) in the United
States. Orion is one of the leading pharmaceutical companies in northern
Europe through its development, manufacturing and marketing of
pharmaceuticals, active pharmaceutical ingredients and diagnostic tests for
global markets. The core therapeutic areas in Orion's product and research
strategy are central nervous system disorders, cardiology, critical care
and hormonal and urological therapies.
Upsher-Smith Laboratories, Inc. is a rapidly growing pharmaceutical
company that manufactures and markets both prescription and consumer
products. Privately held since 1919, the company strives to recognize the
unmet healthcare needs of our customers. Upsher-Smith prides itself in
providing safe, effective, and economical therapies to the ever-challenged
healthcare environment. For additional information about Upsher-Smith,
Page: 1 2 3 4 Related medicine technology :1
|SOURCE Upsher-Smith Laboratories, Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease2
. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium3
. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium4
. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma5
. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG6
. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting7
. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer8
. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients9
. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe10
. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent11
. AGI Dermatics Clinical Data Indicate Bicyclic Monoterpene Diols Suppress MMP1 and Stimulate Collagen Through TNF-a Signaling